Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| DexmedetomidineNCT00226785 | Orion Corporation, Orion PharmaPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| voriconazoleNCT00152594 | University of ColognePHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Ferric saccharose(Venofer®)NCT00210002 | Institut Claudius RegaudPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Darbepoetin alfa (Aranesp®)NCT00210002 | Institut Claudius RegaudPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| bemiparin (low molecular weight heparin)NCT00399425 | Spanish National Health SystemPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Ruta graveolens, 3 DHNCT00222365 | University Hospital, GrenoblePHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Hypericum perforatum, 5 CHNCT00222365 | University Hospital, GrenoblePHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Bryonia alba, 5 CHNCT00222365 | University Hospital, GrenoblePHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Arnica montana, 5 CHNCT00222365 | University Hospital, GrenoblePHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| ZarnestraNCT00210028 | Institut Claudius RegaudPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| TamoxifenNCT00210028 | Institut Claudius RegaudPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-14 |
| Doxil and EstramustineNCT00132756 | Morton Plant Mease Health CarePHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-08 |
| beta-1,3-glucanNCT00276445 | Meiji University of Oriental MedicinePHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-07 |
| Troxatyl™ (Cytotoxic Chemotherapeutic)NCT00104286 | SGX Pharmaceuticals, Inc.PHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-03 |
| Troxatyl™ (troxacitabine)NCT00129948 | SGX Pharmaceuticals, Inc.PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-11-03 |
| Hydralazine and magnesium valproate administrationNCT00395655 | National Institute of CancerologíaPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-03 |
| MVA-MUC1-IL2NCT00040170 | TransgenePHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-02 |
| pegaptanib sodiumNCT00272766 | Barnes Retina InstituteNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-27 |
| L-Ascorbic AcidNCT00329498 | Samsung Medical CenterPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-26 |
| PGI2NCT00291395 | Danish Headache CenterPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-26 |
| Low dose ketamineNCT00224692 | Assistance Publique - Hôpitaux de ParisPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-26 |
| brimonidineNCT00347035 | Federal University of São PauloPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-10-26 |
| HydroxyzineNCT00162786 | J. Uriach and CompanyPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-20 |
| RupatadineNCT00162786 | J. Uriach and CompanyPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-20 |
| 1% pimecrolimus creamNCT00321750 | Centre Hospitalier Universitaire de NicePHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-10-18 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |